Warner Lambert bid to prevent diabetes is set back as NIH halts Rezulin trial
Article Abstract:
Morris Plains, NJ-based Warner-Lambert Co. will halt clinical trials of Rezulin, its drug to prevent diabetes, because of NIH action. The NIH decision came after one patient developed liver failure and subsequently died. The company is now focussing on patients who do not haave diabetes but are at risk of developing the disease. The action affects only those patients involved in experimental preventive treatment and not those with type-2 diabetes who are taking the drug to reduce their blood glucose levels.
Comment:
Will halt clinical trials of Rezulin, its drug to prevent diabetes, because of NIH action
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Pfizer receives 'nonapproval' letter from FDA for antipsychotic Zeldox
Article Abstract:
Pfizer plans to meet with the FDA after receiving a "nonapproval" letter for its new antipsychotic drug, Zeldox, which is intended to treat conditions such as schizophrenia. The setback halts Pfizer's plan to offer Zeldox as an alternative to Eli Lilly & Co.'s Zyprexa, Zeneca Group's Seroquel, and Johnson & Johnson's Risperdal in the growing market for antipyschotic medication. Pfizer hopes to move forward with Zeldox which, like the other new antipsychotic drugs, is expected to bring billions in profit.
Comment:
Zeneca's antipsychotic drug Seroquel may gain larger market share after FDA disapproves Pfizer's Zeldox
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Studies show doctors underprescribe beta blockers for heart-attack patients
Article Abstract:
Two new studies show that more elderly heart-attack patients can be treated by beta blocker drugs than are currently treated. The study states that physicians underprescribe beta blockers because of unfounded concerns about the drug's side effects. The other study asserted that only 50% of ideal beta blocker candidates are released from hospitals, after suffering heart attacks, with the drug.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Disney ordered to pay damages in secrets case. Disney to buy Infoseek stake for Web help. Disney names insider Staggs to succeed Nanula in chief financial officer post
- Abstracts: Guardian Royal to acquire U.S. insurance unit from ING. Nomura sets acquisition of Thorn. Monsanto agrees to acquire Unilever wheat-seed line
- Abstracts: Cargill to buy grain assets from its rival. A big gamble on seeds, drugs gets riskier. An experiment in splicing together two CEOs
- Abstracts: Domtar Inc. to buy E. B. Eddy units of George Weston Air Canada is hit by strike of pilots union. MacMillan Bloedel to unveil limits on logging
- Abstracts: Inacom to purchase Vanstar in $480 million stock swap. Xerox recruits IBM's Firestone as retail chief, rejoining ex-boss